Ginkgo Bioworks Holdings, Inc. DNA R2KR3KPHARMA
Company Overview
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Net profit has compounded at 28.4% per year over the last five years.
Recent Developments
- Dec 2025 Revenue of $170.16M (-25.1% YoY); net profit $-312.76M.
- Trailing 12 Months Year-on-year growth — revenue -48.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -29.1%, profit CAGR 28.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -29.11% |
| 1 Year: | -48.50% |
Compounded Profit Growth
| 5 Years: | 28.38% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -24.66% |
| 6 Months: | +26.94% |
| 3 Months: | +34.09% |
| 1 Month: | -2.54% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)47.35 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 28.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -29.1% CAGR over 5 years.
- Trading 38.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DNA Ginkgo Bioworks Holdings, Inc. R2KR3KPHARMA | 9.99 | -1.97 | $553.28M | 0.00% | -29.68% | -59.94% | -29.11% | 28.38% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.30M | 44.10M | 43.64M | 77.61M | 168.41M | 144.62M | 66.40M | 80.70M | 80.57M | 55.43M | 37.94M | 56.21M | 89.05M | - | 38.23M | 49.60M | 38.84M | 33.40M | 19.47M | 20.16M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.09M | 14.82M | 12.80M | 7.30M | 3.10M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.14M | 34.78M | 26.04M | 26.09M | 16.38M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 110.65M | 96.65M | 114.31M | 96.14M | 87.75M | - |
| Operating Income | -34.41M | -57.12M | -59.95M | -26.67M | -675.37M | -647.78M | -654.94M | -215.75M | -184.15M | -286.39M | -178.00M | -222.94M | -55.20M | - | -76.51M | -61.87M | -88.27M | -70.05M | -71.37M | -58.55M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -61.68M | -45.53M | -74.10M | -66.10M | -58.58M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -83.22M | -60.58M | -80.75M | -81.39M | -76.14M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 88.00K | -283.00K | 1.00K | -643.00K | -80.00K | - |
| Net Income | -26.05M | -73.57M | -53.94M | -101.88M | -590.50M | -668.83M | -670.13M | -204.97M | -173.31M | -302.89M | - | -217.18M | -56.40M | - | -90.96M | -60.30M | -80.75M | -80.75M | -82.59M | -46.71M |
| Diluted EPS | - | - | -0.04 | -0.08 | -0.37 | -0.41 | -0.41 | -0.11 | -0.09 | -6.21 | -3.32 | -4.23 | -1.08 | -2.00 | -1.68 | -1.10 | -1.45 | - | -1.39 | - |
| R&D Expense | 36.07M | 59.59M | 52.03M | 53.02M | 323.58M | 290.06M | 261.46M | 162.64M | 144.28M | 156.66M | 136.46M | 134.22M | 77.01M | - | 70.92M | 53.37M | 69.35M | - | 49.92M | 46.21M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 54.18M | 76.66M | - | 477.71M | 251.46M | 227.04M | 170.16M |
| Cost of Revenue | - | - | - | 204.22M | 54.01M | 44.55M | 46.97M |
| Gross Profit | - | - | - | 273.49M | 197.45M | 182.50M | 123.18M |
| Operating Expenses | - | - | - | 2.48B | 965.65M | 670.22M | 427.06M |
| Operating Income | -71.60M | -137.03M | - | -2.21B | -768.20M | -487.73M | -303.88M |
| EBITDA | - | - | - | -2.08B | -822.34M | -484.39M | -254.61M |
| Interest Expense | - | - | - | 106.00K | 93.00K | 94.00K | 0 |
| Pretax Income | - | - | - | -2.12B | -892.94M | -547.51M | -313.60M |
| Tax Provision | - | - | - | -15.03M | -71.00K | -479.00K | -837.00K |
| Net Income | -119.33M | -126.61M | - | -2.10B | -892.87M | -547.03M | -312.76M |
| Diluted EPS | -0.10 | -0.10 | - | -50.00 | -18.37 | -10.54 | -5.64 |
| R&D Expense | 96.30M | 159.77M | 1.15B | 1.05B | 580.62M | 424.06M | 243.77M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 675.15M | 2.07B | 2.54B | 1.67B | 1.38B | 1.12B |
| Total Equity | 213.43M | 501.85M | 461.38M | 1.51B | 1.74B | 1.10B | 716.06M | 508.59M |
| Cash & Equivalents | - | 495.29M | 380.80M | 1.55B | 1.32B | 944.07M | 561.57M | 167.20M |
| Total Liabilities | - | - | 205.10M | 503.61M | 803.04M | 568.19M | 661.39M | 611.11M |
| Current Liabilities | - | - | 73.22M | 134.76M | 172.96M | 163.86M | 107.27M | 95.97M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -44.66M | -135.83M | -253.82M | -252.20M | -295.50M | -319.58M | -171.06M |
| Investing Cash Flow | -74.60M | -67.12M | -73.26M | -67.39M | -80.69M | -62.24M | -240.29M |
| Financing Cash Flow | 410.38M | 90.32M | 1.53B | 95.34M | -3.22M | -1.74M | 17.77M |
| Capital Expenditure | -22.22M | -57.82M | -56.52M | -52.27M | -40.80M | -62.54M | -7.67M |
| Free Cash Flow | -66.88M | -193.65M | -310.34M | -304.47M | -336.30M | -382.13M | -178.72M |
| Share Buybacks | 408.00K | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 57.3% | 78.5% | 80.4% | 72.4% |
| Operating Margin % | -132.1% | -178.8% | - | -462.4% | -305.5% | -214.8% | -178.6% |
| Net Margin % | -220.2% | -165.2% | - | -440.6% | -355.1% | -240.9% | -183.8% |
| ROE % | -23.8% | -27.4% | - | -121.2% | -81.4% | -76.4% | -61.5% |
| ROCE % | - | -22.8% | - | -93.3% | -51.2% | -38.4% | -29.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.73% | 4.28M | $55.68M |
| 2 | Viking Global Investors, L.P. | 6.46% | 3.58M | $46.50M |
| 3 | Erste Asset Management GmbH | 4.58% | 2.54M | $32.98M |
| 4 | BAILLIE GIFFORD & CO | 4.32% | 2.39M | $31.09M |
| 5 | Vanguard Capital Management LLC | 3.77% | 2.09M | $27.13M |
| 6 | Anchorage Capital Group, LLC | 3.15% | 1.75M | $22.70M |
| 7 | Legal & General Group PLC | 3.01% | 1.67M | $21.70M |
| 8 | State Street Corporation | 2.66% | 1.47M | $19.14M |
| 9 | Geode Capital Management, LLC | 2.21% | 1.22M | $15.89M |
| 10 | Forbes, J.M. & Company | 1.81% | 999.91K | $13.00M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DNA
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE95cnBVc2dTRDJXMFV1Zi1fS1lrVU9XbkQ0R092bWJ3UlNhakhQQ0dHbjVIX1N3VkZXTVd0cGV1VElWdmZUMko5SU9DMmpIWFpz?oc=5" target="_blank">Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price, News, Quo…
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOVzBxSjJFQnRKeXFMQjR4S3hSWi1lY2dzd1ZWbE9fRkszV0tSUGNRQ2xPRVhNNWo1blVhVUZxY2J6TWo0UkIwc2ZLUDBDN0hiOGtBLWJYWFpWQ0xibjBTZ3drRldWNXFjMExhN0NObU9RR0dNcjkwU1o2ckdVNGY3QUtnOWpHNlJPQ2c1TG…
‘We have more in our DNA’: Knorr-Bremse looks beyond rolling stock - Railway Gazette International
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPQ1NuWUctdWdxVFlhSTVLelpzT3Y4ZGNkZFBJeGpSV0o3UmxfMnFSRTRacDZuakVIR1d0MW9udWEzOVJZRGVYd2F6NWtFN28yX3FETVhaTl94T0FSLXBwbjlNYjRkbExXdjRXbkNPbm5YRW1BSWdYcVlsd1VuU095d1NXUDAtYm1GdVZjTk…
Ginkgo Bioworks: Another Curious Rally (NYSE:DNA) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxOZ1dyaEFHSlNHS3NENGZCdHpxa3RsV3k4TXhvd2N0ZGhUdEpSaWFVd1hiVEFIc2EwbVRTRVNOVDJuOFptUE8zVUZlQXhMZGVnczc5WnVVX0RVSF9KRTB4WnVsU3ZseERiRUFLc1dVMlFxTV9FNXZTUzVjalVjV1NjN3RTM2s?oc=5" targ…
DNA - Ginkgo Bioworks Holdings Inc. | News - OTC Markets
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPVHZ4MDdyNEpCMXFadEN5T2h4Q1oxN0R4a3BtZG9RcGgzQWNIWjl4N2tSaXlqY09yRW5VYUN6X3NxM01mTVpnbnh1a1RTSElneFdydWIzLVNGZVBEelduaTQ3d0x4VFZibkROWE8yc3l4cHlwdElLblU1ODdzcVBndXh2dVdWN3RaRG8yVF…
A proposed 22,369-share sale at Ginkgo Bioworks (NYSE: DNA) includes shares to cover taxes. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNbWNYaHV6OUE3a0VHMGxvWk9uRkVJUm9PcnN5N1pTQnpYelhacjRKRVNRcGh2RXV4MXJpNUlzb1hvM1VGemFJQ014aktna1NEQjRNN0dGU011N2dWUmFPVDVfcHEyWThDTU1QMExsLUZwclFCUUg3U1JRLWFJZ0RNYWNRNTBLOUVoYjExVz…
DNA — Frequently Asked Questions
What is the current share price of Ginkgo Bioworks Holdings, Inc. (DNA)?
As of 2026-10-23 16:27 PDT, Ginkgo Bioworks Holdings, Inc. (DNA) trades at $9.99 on NYSE. Its 52-week range is $5.48 to $16.14.
What is the market capitalisation of DNA?
Ginkgo Bioworks Holdings, Inc. (DNA) has a market capitalisation of $553.28M on NYSE.
What is the P/E ratio of DNA?
DNA trades at a trailing price-to-earnings (P/E) ratio of -1.97. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.97.
What is the return on equity (ROE) of DNA?
DNA has a return on equity (ROE) of -59.94%. Its return on capital employed (ROCE) is -29.68%.
Is DNA a good stock to buy?
This page provides a data-driven analysis of Ginkgo Bioworks Holdings, Inc. (DNA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.